2024
Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities
Ruddle N. Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities. Methods In Molecular Biology 2024, 2864: 299-312. PMID: 39527229, DOI: 10.1007/978-1-0716-4184-2_16.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsTertiary lymphoid structuresSecondary lymphoid organsTA-TLSSusceptibility to immune-related adverse eventsAssociated with favorable clinical outcomesPositive response to immunotherapyResponse to immunotherapyFavorable clinical outcomesCellular compositionVascular growth factorsAccumulation of lymphoid cellsCheckpoint inhibitorsLymphoid neogenesisLymphoid structuresProcess of lymphoid neogenesisClinical outcomesAdenovirus vectorLymphoid cellsTumor-associatedAdverse eventsTumor environmentOrgan rejectionChronic inflammation
2019
Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity
Krause P, Kavathas P, Ruddle N. Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity. 2019, 265-276. DOI: 10.1007/978-3-030-25553-4_16.ChaptersSubset of patientsMonoclonal antibodiesSide effectsAutoimmune side effectsRespiratory syncytial virusMinimal side effectsInitial unresponsivenessCheckpoint inhibitorsAdverse eventsField of immunologyCheckpoint inhibitionTreatment failureCytokine inhibitorsSyncytial virusAutoimmune diseasesCancer immunotherapyInhibitory receptorsLate toleranceLung cancerImmune cellsPassive transferImmune regulationImmune responseImmunotherapyLatent infection